Bafna Pharmaceuticals Ltd

📊 Bafna Pharma Q3 2024: Revenue at ₹3,318.76 Lakhs, Returns to Profit

• Q3 2024 revenue from operations: ₹3,318.76 lakhs

• Nine-month revenue: ₹10,679.70 lakhs

• Q3 2024 profit before tax: ₹94.77 lakhs (vs. loss of ₹294.24 lakhs in Q3 2023)

• Nine-month profit before tax: ₹284.18 lakhs

• Q3 2024 EPS: ₹0.40 basic and diluted; nine-month EPS: ₹1.20

• Exceptional items: derecognition of inventory worth ₹1.20 lakhs in Q3 2024 and ₹4.50 lakhs in Q2 2024

• Foreign currency receivables of ₹116 lakhs overdue; seeking RBI approval

• Income tax refund of ₹45.17 lakhs adjusted against demands; writ petition filed

• No outstanding defaults on loans or debt securities as of December 31, 2024